Immuneering Corp

Immuneering Corp.

Biotechnology • Healthcare • Cambridge, MA, United States • IMRX (NGM)

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

617 500 8080 245 Main Street, Cambridge, MA 02142, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 - Seeking Alpha
Seeking Alpha • Dec 30
Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19% - Sahm
Sahm • Dec 28
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? - Yahoo Finance
Yahoo Finance • Nov 26
$IMRX stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
Quiver Quantitative • Dec 23
Immuneering stock soars after reporting 86% survival rate in cancer trial - Investing.com
Investing.com • Sep 24

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Immuneering Corp had layoffs?
No layoff events have been recorded for Immuneering Corp in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Immuneering Corp have?
Immuneering Corp has approximately 54 employees.
What industry is Immuneering Corp in?
Immuneering Corp operates in the Biotechnology industry, within the Healthcare sector.
Is Immuneering Corp a publicly traded company?
Yes, Immuneering Corp is publicly traded under the ticker symbol IMRX on the NGM. The company has a market capitalization of approximately $0.43 billion.
Where is Immuneering Corp headquartered?
Immuneering Corp is headquartered in Cambridge, MA, United States at 245 Main Street, Cambridge, MA 02142, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.